FOI_8275

Internal Reference Number: FOI_8275

Date Request Received: 11/11/2024 00:00:00

Date Request Replied To: 29/11/2024 00:00:00

This response was sent via: By Email

Request Summary: Endometrial Cancer

Request Category: Researcher


Question Number 1: Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Answer To Question 1: Yes.

Question Number 2: How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Lenvatinib + Pembrolizumab (Lenvima +Keytruda) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other Chemotherapy

Answer To Question 2: Patients treated August to October 2024 - Less than 5 patients with the primary diagnosis of endometrial cancer treated with one of the listed drugs.

Question Number 3: In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Answer To Question 3: Less than 5 patients.

Question Number 4: In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other chemotherapy

Answer To Question 4: Chemotherapy and Dostarlimab - Less than 5 patients. Platinum Chemotherapy - Less than 5 patients.

Question Number 5: Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Answer To Question 5: The Trust have no current studies in this area but have had studies in endometrial cancer in the past.

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.